Immune checkpoint inhibitor plus anti-HER2 therapy: a new standard for HER2-positive oesophagogastric cancer?

Affiliations

¹ Department Clinical Oncology, Aichi Cancer Center Hospital, Nagoya 4648681, Japan.
² Department Clinical Oncology, Aichi Cancer Center Hospital, Nagoya 4648681, Japan. Electronic address: kmuro@aichi-cc.jp.

Comment

Yukiya Narita et al. Lancet Oncol. 2020 Jun.

. 2020 Jun;21(6):741-743.

doi: 10.1016/S1470-2045(20)30208-4. Epub 2020 May 18.

¹ Department Clinical Oncology, Aichi Cancer Center Hospital, Nagoya 4648681, Japan.
² Department Clinical Oncology, Aichi Cancer Center Hospital, Nagoya 4648681, Japan. Electronic address: kmuro@aichi-cc.jp.

No abstract available

Comment on

First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial.
Janjigian YY, Maron SB, Chatila WK, Millang B, Chavan SS, Alterman C, Chou JF, Segal MF, Simmons MZ, Momtaz P, Shcherba M, Ku GY, Zervoudakis A, Won ES, Kelsen DP, Ilson DH, Nagy RJ, Lanman RB, Ptashkin RN, Donoghue MTA, Capanu M, Taylor BS, Solit DB, Schultz N, Hechtman JF. Janjigian YY, et al. Lancet Oncol. 2020 Jun;21(6):821-831. doi: 10.1016/S1470-2045(20)30169-8. Epub 2020 May 18. Lancet Oncol. 2020. PMID: 32437664 Free PMC article. Clinical Trial.